PHARMACYTE BIOTECH, INC. Proceeds from Short-term Debt
PHARMACYTE BIOTECH, INC. (PMCB) reported Proceeds from Short-term Debt of $0 for the 12-month period ending 2021-04-30, per its 10-K filed 2021-08-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromShortTermDebt · last filed 2021-08-10
- PHARMACYTE BIOTECH, INC. proceeds from short-term debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- PHARMACYTE BIOTECH, INC. proceeds from short-term debt for fiscal 2020 was $75.20K.
| Period end | Proceeds from Short-term Debt 12 month |
|---|---|
| 2021-04-30 | $0.00 10-K · filed 2021-08-10 |
| 2020-04-30 | $75.20K 10-K · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |